Astellas Venture Management
Brisbane, California, United StatesFounded 2005
Astellas Venture Management primarily invests in early-stage biotechnology companies focused on therapeutic programs and platform technologies for drug discovery and development, aiming to support innovative science that aligns with Astellas Pharma's R&D strategy and addresses unmet medical needs. While mainly active in seed and early-stage investments, they also consider expansion-stage opportunities.
80% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-a (40% of deals). Average disclosed round size is $32.0M (across 3 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Solu Therapeutics | Series A | $41M | Apr 2025 |
 Turn Biotechnologies | Unknown | — | Apr 2022 |
| IIota Biosciences | Series A | $15M | May 2018 |
 eFFECTOR Therapeutics | Series B | $40M | Dec 2015 |
| SSomite.ai | Pre-Seed | — | — |
Top Co-Investors
Eli Lilly and Company1 shared
Pappas Capital1 shared
Longwood Fund1 shared
DCVC Bio1 shared
Alexandria Venture Investments1 shared
LongeVC1 shared
Horizon Ventures1 shared
Bold Capital Partners1 shared
Shanda Group1 shared
Nexus Venture Partners1 shared
Altitude Life Science Ventures1 shared
BioMed Ventures1 shared
Abingworth1 shared
Novartis Venture Fund1 shared
SR One1 shared
The Column Group1 shared
U.S. Venture Partners1 shared
Osage University Partners1 shared
Last updated: 8 March 2026